StreetAlpha.app
Home › Stocks › TRAW

Traws Pharma, Inc. (TRAW)

$0.17
▼ −23.91%
LAST CLOSE · NOV 20

Traws Pharma develops investigational antiviral medicines for respiratory viral diseases such as influenza and COVID-19. It last closed at $0.17 on Nov 20, down 23.91% on the day. The next earnings report for TRAW is expected around Mon, Feb 15, 2027, after the close. For the quarter ended Sep 2026, TRAW reported EPS of -$0.18. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months TRAW insiders bought $998K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TRAW in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TRAW.

Key Stats

Last 12 months
Results
Net income
−$22.3M
EPS (diluted)
−$1.57
Valuation
Market cap
$2.7M
15.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.3M
At Sep 30
Shares outstanding
15.4M
At Nov 12
Employees17 (Apr 8, 2024)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $226K$226KFY2021FY2022: $226K$226KFY2022FY2023: $226K$226KFY2023FY2024: $226K$226KFY2024FY2025: $2.8M$2.8MFY2025

From TRAW's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Feb 15
Estimated date · After the close
Reported EPS
-$0.18
Quarter ended Sep 2026
Year ago EPS
-$0.34
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$3.35Dec '24Mar 2025: $2.09Mar '25Jun 2025: -$0.11Jun '25Sep 2025: -$0.34Sep '25Dec 2025: -$0.71Dec '25Mar 2026: -$0.53Mar '26Jun 2026: -$0.23Jun '26Sep 2026: -$0.18Sep '26Latest -$0.18
Revenue by quarter
Dec 2024: $56,000Dec '24Mar 2025: $57,000Mar '25Jun 2025: $2.7MJun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How TRAW moved after its last 8 reports
Average move the session after a report ±8.3%
Nov 16, 2026After the close−10.3%
Aug 14, 2026After the close−5.4%
May 15, 2026Time not announced+15.3%
Apr 15, 2026After the close−1.6%
Nov 13, 2025Time not announced−17.3%
Aug 14, 2025Time not announced−1.2%
May 15, 2025Time not announced−11.3%
Mar 31, 2025Time not announced−4.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TRAWStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TRAW
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TRAW

Technical Analysis

TRAW · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 53% below its 20 day and 126% below its 50 day average. It is 481% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.17, and the nearest resistance the Pivot at $0.19.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 23.2%/day
Key levels
$3.2352 week high+1800.0%
$1.02200 day average+500.0%
$0.49100 day average+188.2%
$0.4050 day average+135.3%
$0.30Swing high (Nov 12)+76.5%
$0.2720 day average+58.8%
$0.21Pivot R1+23.5%
$0.19Pivot+11.8%
$0.1752 week low+0.0%
$0.17Last close
$0.15Pivot S1−11.8%
Indicators
RSI (14)28.10Oversold below 30Oversold
MACD-0.05Below its signal lineBearish
Stochastic13.9Near the bottom of its rangeOversold
ADX (14)29.9Trending down
Williams %R-95.0Oversold below −80, overbought above −20Oversold
CCI (20)-145.8Oversold below −100, overbought above 100Oversold
Rate of change−21.1%Change over 10 sessionsBearish
ATR (14)$0.04Typical daily range, 23.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TRAW

What happened before

See how TRAW did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for TRAWHow many large options trades hit TRAW, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TRAW Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼9 buying vs 11 selling
  • ▼Held by funds -1.7 pts
  • ▼Funds holding -1
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3334−2.9%
In funds' top 1000–
Held by funds38.4%40.1%−1.7 pts
New / increased5 / 413 / 9−59.1%
Reduced / sold out6 / 58 / 7−26.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TRAW institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TRAW Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$998K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-04 bought $998KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 16Orbimed Advisors LLC10% ownerBuy597,729$1.67$998K
Every insider buy and sale for TRAW over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TRAW insider trades →

From SEC Form 4 filings by TRAW's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRAW is in one of them and how their past TRAW trades turned out.

TRAW in the AI portfolios
Loading…

TRAW News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TRAW in an article yet. Here's the latest on the wider market.

TRAW in the news

About Traws Pharma

Traws Pharma is a clinical stage biopharmaceutical company based in Newtown, Pennsylvania. It is developing investigational antiviral medicines for respiratory viral diseases, including influenza, bird flu and COVID-19. Its main candidate, tivoxavir marboxil, is being studied as a single dose oral treatment and as a monthly oral option to prevent influenza. The company also has cancer programs in clinical development. Its candidates are aimed at patients, and none is yet approved for sale.

Headquarters
Newtown, PA